Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fasitibant
- Development stage
- Phase 2
- Lead developer
- Menarini
- Modality
- Small Molecules
- Administration
- Intraarticular
01
Overview
Fasitibant is a non-peptide, sulfonamide-containing small molecule that acts as a selective antagonist of the bradykinin B2 receptor. It was developed for the treatment of osteoarthritis and investigated primarily as an intra-articular injection for symptomatic osteoarthritis of the knee. Fasitibant inhibits pro-inflammatory responses in vitro and alleviates inflammatory hyperalgesia in animal models by blocking bradykinin-mediated pathways, which are implicated in pain and inflammation. The drug was originally developed by Menarini Group but its development has been discontinued after reaching Phase II clinical trials[1][2][3][5].
- Other names
- fasitibant ionfasitibant cationfasitibant chloridefasitibant chloride hydrochloride
02
Targets
Bradykinin B2 receptor
Beyond the preview
Go deeper on fasitibant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fasitibant.